The estimated Net Worth of Cam L Garner is at least $1.52 Milion dollars as of 10 August 2021. Mr. Garner owns over 10,000 units of Zogenix Inc stock worth over $1,093,880 and over the last 14 years he sold ZGNX stock worth over $0. In addition, he makes $426,018 as Independent Chairman of the Board at Zogenix Inc.
Cam has made over 11 trades of the Zogenix Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ZGNX stock worth $148,300 on 10 August 2021.
The largest trade he's ever made was buying 70,000 units of Zogenix Inc stock on 12 December 2012 worth over $84,700. On average, Cam trades about 5,527 units every 106 days since 2010. As of 10 August 2021 he still owns at least 41,000 units of Zogenix Inc stock.
You can see the complete history of Mr. Garner stock trades at the bottom of the page.
Cam L. Garner serves as Independent Chairman of the Board of the Company. He is one of our co-founders and has served as chairman of our board of directors since August 2006. Mr. Garner co-founded specialty pharmaceutical companies Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc in March 2014), Somaxon Pharmaceuticals, Inc. (sold to Pernix Therapeutics in March 2013), Evoke Pharma, Inc., Elevation Pharmaceuticals, Inc. (sold to Sunovion Pharmaceuticals Inc. in 2012), DJ Pharma (sold to Biovail Corporation in 2000), Verus Pharmaceuticals, Inc., Xcel Pharmaceuticals, Inc. (acquired by Valeant Pharmaceuticals International in 2005), Neurelis, Inc., Meritage Pharma, Inc. (sold to Shire plc in February 2015), and most recently, Kalyra Pharmaceuticals, Inc., OrPro Therapeutics, Inc., Alastin SkinCare and Zavante, Inc. He previously served as chairman of Cadence from May 2004 until March 2014, and served as chairman of Verus, Elevation and Meritage until their acquisition and Evoke since January 2007. Mr. Garner was Chief Executive Officer of Dura Pharmaceuticals, Inc. from 1989 to 1995 and its Chairman and Chief Executive Officer from 1995 to 2000, when it was sold to Elan. In addition to Zogenix, Mr. Garner currently serves as Chairman of Evoke Pharma, a publicly-traded company, Kalyra Pharamaceuticals, OrPro, Alastin and Zavante, and serves on the Board of Directors of Aegis and Neurelis. Mr. Garner is also Chairman-elect and serves on the Executive Committee of UCSD Moores Cancer Center, San Diego. Mr. Garner earned his B.A. in Biology from Virginia Wesleyan College and an M.B.A. from Baldwin-Wallace College.
As the Independent Chairman of the Board of Zogenix Inc, the total compensation of Cam Garner at Zogenix Inc is $426,018. There are 11 executives at Zogenix Inc getting paid more, with Stephen Farr having the highest compensation of $10,346,800.
Cam Garner is 71, he's been the Independent Chairman of the Board of Zogenix Inc since 2006. There are no older and 22 younger executives at Zogenix Inc.
Cam's mailing address filed with the SEC is C/O EVOKE PHARMA, INC., 420 STEVENS AVENUE, SUITE 230, SOLANA BEACH, CA, 92075.
Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo a Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: